1
Ishikawa Rika, Okada Yuji, Kakitani Makoto: Chemically modified granulocyte colony stimulating factor.. Kirin Amgen, December 12, 1990: EP0401384-A1 (353 worldwide citation)

A new chemically modified protein consists of human granulocyte colony stimulating factor (G-CSF) (aminoacid sequence of 174 units ( or 175 with N-terminal methionine) given in the patent) (expressed by host cells from a foreign DNA sequence) bound to polyethylene glycol either through the amino gps ...


2
Fu Kuen Lin: DNA sequences encoding erythropoietin. Kiren Amgen, Michael F Borun, Steven M Odre, October 27, 1987: US04703008 (288 worldwide citation)

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous ...


3
Olaf B Kinstler, Nancy E Gabriel, Christine E Farrar, Randolph B DePrince: N-terminally chemically modified protein compositions and methods. Amgen, Robert B Winter, Karol M Pessin, Steven M Odre, October 20, 1998: US05824784 (274 worldwide citation)

Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and relate ...


4
Graham Beaton, Eric F Fisher: Modified oligonucleotides and intermediates useful in nucleic acid therapeutics. Amgen, Ron K Levy, Steven M Odre, April 29, 1997: US05625050 (266 worldwide citation)

The present invention provides nuclease resistant 3'-carbon modified oligonucleotides that can be used in the field of nucleic acid therapeutics and diagnostics. The modified oligonucleotides of the present invention have at least one modified internucleotide linkage wherein the divalent oxygen moie ...


5
Ulrich Feige, Chuan Fa Liu: Modified peptides as therapeutic agents. Amgen, Timothy J Gaul, Ron K Levy, Steven M Odre, December 9, 2003: US06660843 (240 worldwide citation)

The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising:


6
Lawrence M Souza: Production of pluripotent granulocyte colony-stimulating factor. Kirin Amgen, Michael F Borun, Steven M Odre, March 7, 1989: US04810643 (228 worldwide citation)

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of pr ...


7
Robert M Platz, Mark A Winters, Colin G Pitt: Pulmonary administration of granulocyte colony stimulating factor. Amgen, Richard J Mazza, February 8, 1994: US05284656 (188 worldwide citation)

Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in a ...


8
Rika Ishikawa, Yuji Okada, Makoto Kakitani: Chemically-modified G-CSF. Kirin Amgen, Marshall O Toole Gerstein Murray & Borun, October 20, 1998: US05824778 (153 worldwide citation)

The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: ##STR1## The chemically-modif ...


9
Fu Kuen Lin: Production of recombinant erythropoietin. Kirin Amgen, Marshall O Toole Gerstein Murray & Borun, August 15, 1995: US05441868 (150 worldwide citation)

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous ...


10
Fu Kuen Lin: Production of erythropoietin. Kirin Amgen, Marshall O Toole Gerstein Murray & Borun, August 20, 1996: US05547933 (150 worldwide citation)

Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin ("EPO") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous ...